Administration of CardiolRx™ led to a marked reduction in the primary efficacy endpoint of pericarditis painCardiolRx™ also shown to reduce inflammation in patients with elevated CRP89% of patients have continued into the extension phase of the studyToronto, Ontario--(Newsfile Corp. - June 13, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and a
Copperleaf Technologies Inc. (T.CPLF) hit a new 52-week high of $11.87 Tuesday. IFS, the leading technology ...
Cardiol Therapeutics Inc. (T.CRDL) hit a new 52-week high of $3.61 Tuesday. No news stories available ...